Physician profile
Anna Carolina Wright
NPI 1649767310
$68,736.61
in general payments reported to CMS, 2019-2025
34 companies · $24K in 2025
The $24K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,488 · 2022: $3,601 · 2023: $22K · 2024: $18K · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $22K · Honoraria: $14K · Food and Beverage: $12K · Consulting Fee: $11K · Travel and Lodging: $3,946 · Education: $127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $22,250.00 |
| Honoraria | $14,000.00 |
| Food and Beverage | $12,075.27 |
| Consulting Fee | $11,250.00 |
| Travel and Lodging | $3,945.58 |
| Education | $127.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $30,288.97 | 2023-2025 | Auvelity |
| Abbvie INC. | $25,035.71 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $2,657.68 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,514.10 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $1,367.21 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $1,319.92 | 2021-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Alkermes, INC. | $994.03 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Neurocrine Biosciences, INC. | $845.14 | 2022-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $602.57 | 2021-2025 | Trintellix |
| Neos Therapeutics, LP | $566.73 | 2021-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Supernus Pharmaceuticals, INC. | $553.04 | 2021-2025 | Qelbree, Qelbree |
| Corium, LLC | $443.01 | 2021-2025 | Azstarys |
| Noven Therapeutics, LLC | $431.78 | 2021-2025 | Xelstrym, Secuado |
| Lundbeck LLC | $295.62 | 2021-2025 | Rexulti, Abilify Maintena |
| Tris Pharma INC | $292.27 | 2023-2025 | Dyanavel Xr, Onyda Xr |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $256.46 | 2024-2025 | Fanapt |
| Indivior INC. | $248.18 | 2022-2024 | Perseris |
| E.R. Squibb & Sons, L.L.C. | $160.82 | 2024-2025 | Cobenfy |
| Almatica Pharma LLC | $114.21 | 2023-2025 | Loreev Xr, Sertraline Hcl |
| Sunovion Pharmaceuticals INC. | $101.12 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $89.89 | 2023 | Spravato |
| Idorsia Pharmaceuticals US INC | $77.71 | 2023-2024 | Quviviq |
| Vertical Pharmaceuticals, LLC | $72.97 | 2024-2025 | Relexxii |
| Luye Pharma (USA) LTD. | $63.27 | 2025 | Erzofri Extended-Release |
| Ironshore Pharmaceuticals INC. | $61.24 | 2022-2024 | |
| Adlon Therapeutics L.P. | $53.51 | 2021 | |
| Merck Sharp & Dohme LLC | $42.71 | 2022-2023 | Belsomra |
| Bausch Health US, LLC | $41.46 | 2024-2025 | Wellbutrin, Aplenzin |
| Aytu Biopharma, INC. | $39.15 | 2021-2022 | |
| Avion Pharmaceuticals | $36.48 | 2023 | Methylphenidate Hydrochloride |
| Lilly USA, LLC | $22.81 | 2025 | Zepbound |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.46 | 2025 | Abilify Maintena |
| Collegium Pharmaceutical, INC. | $16.35 | 2025 | Jornay Pm |
| Tempus Ai, INC | $14.03 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Carolina Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.